Document Detail


Second generation antidepressants.
MedLine Citation:
PMID:  6969258     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
One approach to research into depressive illness includes a clinical pharmacotherapeutic tack such as the use of investigational drugs with defined pharmacological and biochemical activity. Using this research strategem, a variety of new compounds have been investigated in recent years all of which are unique chemically; all differ from the classic tricyclic-MAOI compounds. Animal pharmacology and neurochemical studies also show a profile which largely differs from the standard reference compounds. Their effects on central monoamine metabolism differ widely; some act pre- and others postsynaptically, some act by re-uptake inhibition, others by enhancing release, others are precursors, while still others are receptor agonists; some have no apparent central effect. The data, considered collectively and critically evaluated, suggest that many of the newer compounds used investigationally, because of their clinical efficacy, seriously question the involvement of monoamines as responsible for either the antidepressant effect of the standard psychotropic drugs or as etiopathogenic in the affective disorders. The classic animal screening profiles used for predicting antidepressant drug efficacy in man do not hold for many of these newer antidepressants. the animal-laboratory models need be revised and reoriented towards finding similar molecules that are devoid of the addling side effects and contraindications of the existing standard tricyclic-MAOI genre. The newer second generation antidepressants stand as a hallmark of progress in research and treatment with psychotropic drugs.
Authors:
B Shopsin
Related Documents :
6848988 - Drug therapy for depression in the elderly.
1638458 - A review of schizoaffective disorder: ii. somatic treatment.
8615378 - Case report: interaction of rifampin and nortriptyline.
6194518 - Antidepressant properties of some phosphodiesterase inhibitors.
21220138 - Polyphosphazene nanoparticles for cytoplasmic release of doxorubicin with improved cyto...
19950388 - Drug transporters in the lung--do they play a role in the biopharmaceutics of inhaled d...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Journal of clinical psychiatry     Volume:  41     ISSN:  0160-6689     ISO Abbreviation:  J Clin Psychiatry     Publication Date:  1980 Dec 
Date Detail:
Created Date:  1981-02-24     Completed Date:  1981-02-24     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7801243     Medline TA:  J Clin Psychiatry     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  45-56     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antidepressive Agents, Tricyclic / therapeutic use*
Catecholamines / metabolism
Depressive Disorder / drug therapy*,  metabolism
Double-Blind Method
Fluoxetine / therapeutic use
Humans
Imipramine / therapeutic use
Monoamine Oxidase Inhibitors / therapeutic use*
Nomifensine / therapeutic use
Serotonin / metabolism
Trazodone / therapeutic use
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Tricyclic; 0/Catecholamines; 0/Monoamine Oxidase Inhibitors; 19794-93-5/Trazodone; 24526-64-5/Nomifensine; 50-49-7/Imipramine; 50-67-9/Serotonin; 54910-89-3/Fluoxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Psychiatric treatment and record organized by objectives.
Next Document:  Complementation of subunits from different bacterial luciferases. Evidence for the role of the beta ...